regulatory status comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
== Structure == VEGFR-2 are a part of the VEGF family. The other receptors in the family are VEGFR-1 and VEGFR-3. These receptors are a type of transmembrane kinase receptors and have similar structure. They have an extracellular part that is made up of an N-terminus signal and a 7 immunoglobulin-like domain. The intracellular part of the receptor consists of a juxtamembrane (the tyrosine kinase domain), which is divided to proximal and distal kinase domains and a C-terminus tail.
== Side effects == Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.
== Design == The newer TGI Fridays franchises (as well as redesigned restaurants) are more contemporary, with wallpaper, granite exteriors, and red-and-white striped lamps instead of Tiffany. The exteriors have stucco, the entrance doors have F-shaped handles, and a metal cup above the door has a stripe saying "In Here, It's always Friday". The logo design was evolved in 2013 by Jane MacDowall and her creative team in Scotland. Most TGI Fridays have a propeller and a rowing scull on display as part of their antiques, which are actually a part of a story told to all TGI Fridays employees; the scull always contains a pair of saddle shoes and a bottle of champagne to remind employees of the value of teamwork, leadership, and celebrating success. The propeller is always above or near the bar. The thought is that the bar "propels" the restaurant.
== Toxicity == There has been very little mention of toxicity in most published animal studies using Colostrinin, which may suggest that it exhibits low toxicity. Generally, treatment with Colostrinin in clinical studies has been well tolerated by both animals and humans, with any side-effects being mild and transient.
Sources: en.wikipedia.org
=== Marxism and socialism === In a 2001 interview with Reason, Hitchens said he became a Marxist and a Trotskyist in his teens, beliefs that further developed during his time at Balliol College, Oxford. In 1966, he was demonstrating in Trafalgar Square against the Vietnam War. In 1967, he joined the International Socialists while at Balliol College, Oxford. Under the influence of Peter Sedgwick, who translated the writings of Russian revolutionary and Soviet dissident Victor Serge, Hitchens forged an ideological interest in Trotskyist and anti-Stalinist socialism. Shortly after he joined "a small but growing post-Trotskyist Luxemburgist sect". This organisation is now known as the Alliance for Workers' Liberty. He became a socialist "largely [as] the outcome of a study of history, taking sides ... in the battles over industrialism and war and empire." He was also drawn into the political left by his anger over the Vietnam War, nuclear weapons, racism and "oligarchy", including that of "the unaccountable corporation." He also said in the same interview with Reason that he could no longer say "I am a socialist". Socialists, he claimed, had ceased to offer a positive alternative to the capitalist system. In a June 2010 interview with The New York Times, he stated that "I still think like a Marxist in many ways. I think the materialist conception of history is valid. I consider myself a very conservative Marxist".
=== Bleaching === About 60% of the world's production of hydrogen peroxide is used for pulp- and paper-bleaching. The second major industrial application is the manufacture of sodium percarbonate and sodium perborate, which are used as mild bleaches in laundry detergents. A representative conversion is:
=== SCTECH - Supply Chain Technology Conference and Expo === Since 2016 ISCEA has sponsored and managed a supply chain technology conference and expo named SCTECH. Besides being a Supply Chain, Operations, Engineering and Technology professionals gathering, SCTECH provides Professional Development Units (PDUs) to ISCEA's certified professional so that they can renew their certification credentials. The event has an itinerant nature. Its first edition was held in Chicago and following editions were held in Mexico and Paris. Since 2023, SCTECH has offered a Virtual Program with global outreach, along with an In-Person Executive Program for Supply Chain Leaders. The Executive Programs for both the 2023 and 2024 editions took place at SAP’s World Headquarters in Walldorf, Germany.
=== International expansion === The company's first international move took it to Russia in 1992. There, Dr. Reddy's formed a joint venture with the country's biggest pharmaceuticals producer, Biomed. They pulled out in 1995 amid accusations of scandal, involving "a significant material loss due to the activities of Moscow's branch of Reddy's Labs with the help of Biomed's chief executive". Reddy's sold the joint venture to the Kremlin-friendly Sistema group. In 1993, Reddy's entered into a joint venture in the Middle East and created two formulation units there and in Russia. Reddy's exported bulk drugs to these formulation units, which then converted them into finished products. In 1994, Reddy's started targeting the US generic market by building state of art manufacturing facility.
== Origin and properties == The Natural History by the Roman writer Pliny the Elder includes a few sentences about a volcanic glass called obsidian (lapis obsidianus), discovered in Ethiopia by Obsidius, a Roman explorer. Obsidian is formed from quickly cooled lava. Extrusive formation of obsidian may occur when felsic lava cools rapidly at the edges of a felsic lava flow or volcanic dome, or when lava cools during sudden contact with water or air. Intrusive formation of obsidian may occur when felsic lava cools along the edges of a dike. Tektites were once thought by many to be obsidian produced by lunar volcanic eruptions, though few scientists now adhere to this hypothesis. Obsidian is mineral-like, but not a true mineral because, as a glass, it is not crystalline; in addition, its composition is too variable to be classified as a mineral. It is sometimes classified as a mineraloid. Though obsidian is usually dark in color, similar to mafic rocks such as basalt, the composition of obsidian is extremely felsic. Obsidian consists mainly of SiO2 (silicon dioxide), usually 70% by weight or more; the remainder consists of variable amounts of other oxides, mostly oxides of aluminium, iron, potassium, sodium and calcium. Crystalline rocks with a similar composition include granite and rhyolite. Because obsidian is metastable at the Earth's surface (over time the glass devitrifies, becoming fine-grained mineral crystals), obsidian older than Miocene in age is rare. Exceptionally old obsidians include a Cretaceous welded tuff and a partially devitrified Ordovician perlite.
Sources: en.wikipedia.org
Dermatitis (characteristic "broad collar" rash known as casal collar) Hair loss Swelling Smooth, beefy red glossitis (tongue inflammation) Trouble sleeping Weakness Mental confusion or aggression Ataxia (lack of coordination), paralysis of extremities, peripheral neuritis (nerve damage) Diarrhea Dilated cardiomyopathy (enlarged, weakened heart) Sensitivity to radiation Eventually dementia J. Frostigs and Tom Spies—according to Cleary and Cleary—described more specific psychological symptoms of pellagra as:
Attempts to reunite the Polish lands gained momentum in the 13th century, and in 1295, Duke Przemysł II of Greater Poland managed to become the first ruler since Bolesław II to be crowned king of Poland. He ruled over a limited territory and was soon killed. In 1300–1305 King Wenceslaus II of Bohemia also reigned as king of Poland. The Piast Kingdom was effectively restored under Władysław I the Elbow-high (r. 1306–1333), who became king in 1320. In 1308, the Teutonic Knights seized Gdańsk and the surrounding region of Pomerelia. King Casimir III the Great (r. 1333–1370), Władysław's son and the last of the Piast rulers, strengthened and expanded the restored Kingdom of Poland, but the western provinces of Silesia (formally ceded by Casimir in 1339) and most of Polish Pomerania were lost to the Polish state for centuries to come. Progress was made in the recovery of the separately governed central province of Mazovia, however, and in 1340, the conquest of Red Ruthenia began, marking Poland's expansion to the east. The Congress of Kraków, a vast convocation of central, eastern, and northern European rulers probably assembled to plan an anti-Turkish crusade, took place in 1364, the same year that the future Jagiellonian University, one of the oldest European universities, was founded. On 9 October 1334, Casimir III confirmed the privileges granted to Jews in 1264 by Bolesław the Pious and allowed them to settle in Poland in great numbers.
Eventually, explanation what implies "the balance of power favoring freedom" was dropped by "US National Security and Defense Strategies" of 2018: The Pentagon will ensure that the United States remain the "preeminent military power in the world," and the regional "balances of power remain in our favor." [Emphasis added] The "balance of power favoring freedom" appeared identical with the balance of power favoring "us." Russian President Vladimir Putin complained: "Instead of establishing a new balance of power … they [the United States] took steps that threw the [international] system into sharp and deep imbalance." In 1826, George Canning "called the new world into existence to redress the balance of the old". In 1898, Theodore Roosevelt found that the United States had become "more and more the balance of power of the whole globe." In 1941, a New Deal Economist with the National Resources Planning Board, Otto T. Mallery, averred that "destiny offers to the United States the ultimate balance of power and of resources in the world after the war." Colin Gray titled his 2005 chapter by question, "Where Is the Balance of Power?" The chapter opens: "The short answer is that the United States is the balance of power."
In 1800, France built Nautilus, a human-powered submarine designed by American Robert Fulton. They gave up on the experiment in 1804, as did the British, when they reconsidered Fulton's submarine design. In 1850, Wilhelm Bauer's Brandtaucher was built in Germany. It remains the oldest known surviving submarine in the world. In 1864, late in the American Civil War, the Confederate navy's H. L. Hunley became the first military submarine to sink an enemy vessel, the Union sloop-of-war USS Housatonic, using a gun-powder-filled keg on a spar as a torpedo charge. The Hunley also sank. The explosion's shock waves may have killed its crew instantly, preventing them from pumping the bilge or propelling the submarine. In 1866, Sub Marine Explorer was the first submarine to successfully dive, cruise underwater, and resurface under the crew's control. The design by German American Julius H. Kroehl (in German, Kröhl) incorporated elements that are still used in modern submarines. In 1866, Flach was built at the Chilean government's request by Karl Flach, a German engineer and immigrant. It was the fifth submarine built in the world and, along with a second submarine, was intended to defend the port of Valparaíso against attack by the Spanish Navy during the Chincha Islands War.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.